S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
NASDAQ:TYRA

Tyra Biosciences (TYRA) Stock Forecast, Price & News

$13.46
-0.38 (-2.75%)
(As of 09/26/2023 ET)
Compare
Today's Range
$13.19
$14.00
50-Day Range
$13.15
$16.08
52-Week Range
$5.50
$19.74
Volume
57,472 shs
Average Volume
39,139 shs
Market Capitalization
$578.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

Tyra Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
78.3% Upside
$24.00 Price Target
Short Interest
Bearish
9.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.38mentions of Tyra Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$772,507 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.32) to ($1.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

718th out of 964 stocks

Pharmaceutical Preparations Industry

321st out of 438 stocks


TYRA stock logo

About Tyra Biosciences (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 which is in Phase 1/2 clinical trial for the treatment of patients with mUC and other solid tumors. The company is also developing TYRA-300 for long-term complications associated with skeletal conditions including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes. Its product pipeline also includes TYRA-200, an FGFR1/2/3 inhibitor with potency FGFR2 fusions and molecular brake mutations for bile duct and solid tumors; FGF19+/FGFR4, a FGFR4-specific inhibitor that is active in the presence of the V550 gatekeeper and the C552 Cys mutations for liver and solid tumors; and RET, a specific inhibitor that is active in the presence of the V804 gatekeeper and the G810 solvent front mutations for the treatment of lung and thyroid cancer. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

TYRA Price History

TYRA Stock News Headlines

Tyra Biosciences (NASDAQ:TYRA) Shares Up 4.8%
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Tyra Biosciences Inc.
Analyst Ratings for Tyra Biosciences
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
H.C. Wainwright Remains a Buy on Tyra Bioscience (TYRA)
Where Tyra Biosciences Stands With Analysts
H.C. Wainwright Keeps Their Buy Rating on Tyra Bioscience (TYRA)
The Latest Analyst Ratings for Tyra Biosciences
Tyra Bioscience (TYRA) Gets a Buy from H.C. Wainwright
See More Headlines
Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

TYRA Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TYRA
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+78.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-55,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.11 per share

Miscellaneous

Free Float
35,097,000
Market Cap
$578.93 million
Optionable
Not Optionable
Beta
0.90
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Todd Harris Ph.D. (Age 44)
    Co-Founder, Pres, CEO, Sec., Treasurer & Director
    Comp: $903.33k
  • Mr. Daniel Bensen (Age 48)
    Co-Founder & COO
    Comp: $630.8k
  • Mr. Ali D. Fawaz J.D.
    Gen. Counsel & Sec.
  • Mr. Alan Fuhrman (Age 66)
    Chief Financial Officer
  • Dr. Robert L. Hudkins Ph.D. (Age 68)
    Chief Technology Officer
  • Dr. Ronald V. Swanson Ph.D. (Age 60)
    Chief Scientific Officer
  • Ms. Sarah Honig
    VP of Corp. Devel. & Strategy
  • Dr. Hiroomi Tada M.D. (Age 59)
    Ph.D., Chief Medical Officer
  • Dr. Piyush R. Patel Ph.D. (Age 58)
    Chief Devel. Officer
  • Amy Conrad
    Investor Contact













TYRA Stock - Frequently Asked Questions

Should I buy or sell Tyra Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TYRA shares.
View TYRA analyst ratings
or view top-rated stocks.

What is Tyra Biosciences' stock price forecast for 2023?

3 brokers have issued 12 month price targets for Tyra Biosciences' stock. Their TYRA share price forecasts range from $20.00 to $27.00. On average, they predict the company's share price to reach $24.00 in the next year. This suggests a possible upside of 78.3% from the stock's current price.
View analysts price targets for TYRA
or view top-rated stocks among Wall Street analysts.

How have TYRA shares performed in 2023?

Tyra Biosciences' stock was trading at $7.60 at the beginning of 2023. Since then, TYRA stock has increased by 77.1% and is now trading at $13.46.
View the best growth stocks for 2023 here
.

When is Tyra Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our TYRA earnings forecast
.

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences, Inc. (NASDAQ:TYRA) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.03.

What ETF holds Tyra Biosciences' stock ?

Range Cancer Therapeutics ETF holds 7,883 shares of TYRA stock, representing 1.17% of its portfolio.

When did Tyra Biosciences IPO?

(TYRA) raised $100 million in an initial public offering on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share.

What is Tyra Biosciences' stock symbol?

Tyra Biosciences trades on the NASDAQ under the ticker symbol "TYRA."

Who are Tyra Biosciences' major shareholders?

Tyra Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BVF Inc. IL (6.37%), BlackRock Inc. (2.09%), JPMorgan Chase & Co. (0.99%), Perceptive Advisors LLC (0.84%), Geode Capital Management LLC (0.68%) and State Street Corp (0.60%). Insiders that own company stock include Boxer Capital, Llc, Daniel Bensen, Mva Investors, Llc and Todd Harris.
View institutional ownership trends
.

How do I buy shares of Tyra Biosciences?

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyra Biosciences' stock price today?

One share of TYRA stock can currently be purchased for approximately $13.46.

How much money does Tyra Biosciences make?

Tyra Biosciences (NASDAQ:TYRA) has a market capitalization of $578.93 million. The company earns $-55,330,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How can I contact Tyra Biosciences?

Tyra Biosciences' mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The official website for the company is www.tyra.bio. The company can be reached via phone at 619-728-4760 or via email at aconrad@tyra.bio..

This page (NASDAQ:TYRA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -